Skip to main content

Zytiga News

FDA Approves Akeega for BRCA-Positive Metastatic Prostate Cancer

THURSDAY, Aug. 17, 2023 – The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate...

Sun Pharma Announces FDA Approval of Yonsa (abiraterone acetate) to Treat Metastatic Castration-Resistant Prostate Cancer

MUMBAI & PRINCETON, N.J. & KING OF PRUSSIA, Pa. May 23, 2018 --(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. and includes its subsidiaries and/or associate companies) and Churchill...

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (...

FDA Expands Zytiga’s Use for Late-Stage Prostate Cancer

December 10, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Prostate Cancer

Zytiga patient information at Drugs.com